Compare DexCom, Inc. (DXCM) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Entegris Inc — how do they compare? DexCom, Inc. trades at $77.55 (market cap $28.06B), while Entegris Inc trades at $135.09 (market cap $21.12B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Entegris Inc pays a 0.29% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ENTG | |
|---|---|---|
Market Cap | $28.06B | $21.12B |
Sector | Health | Technology |
52-Week High | $89.53 | $184.00 |
52-Week Low | $54.84 | $68.80 |
Enterprise Value | $27.03B | $24.44B |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Entegris (ENTG) trades at $140.63, up 3.2% on the day, with a bearish technical signal and premium valuation metrics. The company reported strong Q1 2026 earnings, beating estimates, and maintains a solid cash flow position. Recent news highlights a quarterly dividend declaration and a non-exclusive cross-licensing agreement for EUV lithography technology.
The outlook is mixed: Wall Street analysts maintain a bullish consensus with a $178.40 price target (26.9% upside), citing AI-driven semiconductor demand as a catalyst. However, risks include elevated valuation multiples, competitive pressures in the semiconductor materials sector, and execution challenges in maintaining recent earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
